Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effectiveness of Family-Focused Treatment Plus Pharmacotherapy for Bipolar Disorder in Adolescents

16 maj 2014 uppdaterad av: David J. Miklowitz, Ph.D., University of California, Los Angeles

Family-Focused Treatment for Bipolar Adolescents

This study will evaluate the effectiveness of family-focused treatment (FFT) plus pharmacotherapy in treating adolescents with bipolar disorder.

Studieöversikt

Detaljerad beskrivning

Bipolar disorder is a serious mental illness that causes drastic shifts in a person's mood, energy, and ability to function. Bipolar disorder can strike at any age, but it most commonly develops in late adolescence or early adulthood. The disorder is characterized by alternating episodes of mania and depression, often with periods of normal mood in between. Some symptoms of a manic episode include the following behaviors: increased energy, activity, and restlessness; excessively "high," overly good, euphoric mood; and extreme irritability. In contrast, a depressive episode is characterized by a lasting sad, anxious, or empty mood; feelings of hopelessness or pessimism; and decreased energy. Adolescents with bipolar disorder have high rates of disease recurrence, suicide attempts, functional impairment, and mental health service utilization, even with aggressive treatment with mood stabilizers and antipsychotic drugs. Research has suggested that FFT, a behavioral intervention consisting of psychoeducation, communication training, and problem solving training, may lead to improvements in mood symptoms in adolescents with bipolar disorder. This study will evaluate the effectiveness of FFT plus pharmacotherapy in treating adolescents with bipolar illness.

Participants in this 2-year, single-blind study will be randomly assigned to receive a combination of either FFT and pharmacotherapy or enhanced care and pharmacotherapy. Medications used for the pharmacotherapy portion of the study will include mood stabilizers, such as lithium or divalproex sodium, and atypical antipsychotics, such as quetiapine. Participants will also receive anti-anxiety medications, psychostimulants, or antidepressants as needed. All participants will receive pharmacotherapy for the full 2 years. Participants assigned to enhanced care will take part in weekly brief psychoeducation sessions for 3 weeks. Participants assigned to FFT will take part in weekly treatment sessions with their families for 12 weeks, biweekly for 12 weeks, monthly for 3 months, and then trimonthly until Month 24. Both FFT and enhanced care treatment sessions will include psychoeducation focusing on appropriate ways to manage bipolar disorder and its cycling nature. Crisis intervention sessions will also be offered to all participants on an as-needed basis for the duration of the study. Outcomes, including bipolar disorder symptoms, functioning, and service utilization, will be measured at study visits at Months 3, 6, 9, 12, 18, and 24.

Studietyp

Interventionell

Inskrivning (Faktisk)

145

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Colorado
      • Boulder, Colorado, Förenta staterna, 80309-0345
        • University of Colorado, Dept. of Psychology
    • Ohio
      • Cincinnati, Ohio, Förenta staterna, 45229
        • Cincinnati Children's Hospital Medical Center/MLC 3014
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Förenta staterna, 15213
        • University of Pittsburgh Medical Center Western Psychiatric Institute

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

13 år till 17 år (Barn)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Between the ages of 13 years, 0 months and 17 years, 11 months
  • Meets The Diagnostic and Statistical Manual of Mental Disorders - IV criteria for either of the following conditions: bipolar I or bipolar II disorder with a manic, mixed, or hypomanic episode within 3 months of study entry; or a depressed episode within 3 months of study entry with a prior history of a manic, hypomanic, or mixed episode (if the participant only meets criteria for a current hypomanic episode, there must also be a history of at least one prior depressive, manic, or mixed episode)
  • Has experienced severe depression, hypomania, or mania symptoms for a period of at least 1 week within the 3 months prior to study entry
  • Lives with at least one biological or step-parent who is available and willing to participate in treatment (parents not currently living with the adolescent participant may also participate)

Exclusion Criteria:

  • Currently in full recovery (experienced minimal symptoms for at least 8 continuous weeks)
  • Meets Diagnostic and Statistical Manual of Mental Disorders, IV criteria for substance abuse disorder or substance dependence disorder within 3 months of study entry (based on the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version )
  • Meets current criteria for bipolar, not otherwise specified, or substance-induced mood disorder
  • Diagnosis of mental retardation, autism, or organic central nervous system disorder
  • Severe, unremitting psychosis that is unresponsive to neuroleptic medications, and has lasted more than 3 months
  • Requires extended inpatient treatment (although participant can be hospitalized at the time of intake into the study)
  • Current life-threatening eating disorder, neurological condition, or other medical problem that requires immediate treatment
  • Exhibits or expresses serious homicidal tendencies
  • Victim of current sexual or physical abuse by parents or is in an environment marked by domestic violence among the parents or step-parents

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: 1
Family-Focused Treatment Plus Pharmacotherapy
Participants assigned to FFT will take part in weekly treatment sessions with their families for 12 weeks, biweekly for 12 weeks, monthly for 3 months, and then trimonthly until Month 24. Medications used for the pharmacotherapy portion of the study will include mood stabilizers, such as lithium or divalproex sodium, and atypical antipsychotics, such as quetiapine. Participants will also receive anti-anxiety medications, psychostimulants, or antidepressants as needed.
Aktiv komparator: 2
Enhanced Care Plus Pharmacotherapy
Participants assigned to Enhanced Care will take part in weekly brief psychoeducation sessions for 3 weeks. The pharmacotherapy treatment will be the same as for the FFT participants.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Time to recovery
Tidsram: Measured at Month 24
Measured at Month 24
Time to recurrence
Tidsram: Measured at Month 24
Measured at Month 24
Severity of manic and depressive symptoms
Tidsram: Measured at Month 24
Measured at Month 24

Sekundära resultatmått

Resultatmått
Tidsram
Functioning
Tidsram: Measured at Month 24
Measured at Month 24
Quality of life
Tidsram: Measured at Month 24
Measured at Month 24
Service utilization
Tidsram: Measured at Month 24
Measured at Month 24

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: David J. Miklowitz, PhD, University of Colorado at Boulder
  • Huvudutredare: Robert A. Kowatch, MD, University of Cincinnati
  • Huvudutredare: David A. Axelson, MD, University of Pittsburgh Medical Center

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 augusti 2006

Primärt slutförande (Faktisk)

1 juli 2012

Avslutad studie (Faktisk)

1 juli 2012

Studieregistreringsdatum

Först inskickad

30 maj 2006

Först inskickad som uppfyllde QC-kriterierna

30 maj 2006

Första postat (Uppskatta)

1 juni 2006

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

20 maj 2014

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 maj 2014

Senast verifierad

1 maj 2014

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • R01MH073871 (U.S.S. NIH-anslag/kontrakt)
  • DSIR 84-CTS (Division of Services and Intervention Research)
  • R01MH073817 (U.S.S. NIH-anslag/kontrakt)
  • R01MH074033 (U.S.S. NIH-anslag/kontrakt)

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Family-Focused Treatment Plus Pharmacotherapy

3
Prenumerera